Healthcare Services

Vitreoretinal Disorder Market Industry Analysis Covering Trends, Drivers, And Future Outlook

June 4, 2026June 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Vitreoretinal Disorder Market By 2030 Based On Its 2026 Value?

The vitreoretinal disorder market has experienced substantial expansion in recent years. It is projected to increase from $4.63 billion in 2025 to $4.99 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.9%. This historical growth can be attributed to several factors including the increasing prevalence of diabetic eye diseases, broader availability of optical coherence tomography, a rise in ophthalmic surgical procedures, the expansion of specialty eye clinics, and enhanced diagnostic accuracy.

The vitreoretinal disorder market size is projected to experience substantial growth in the coming years. It is anticipated to reach $6.71 billion by 2030, at a compound annual growth rate (CAGR) of 7.7%. This growth over the forecast period is attributed to factors such as increasing demand for personalized retinal treatments, rising investments in ophthalmic innovation, the expansion of minimally invasive surgical techniques, the growing use of AI-driven diagnostics, and an increasing focus on vision preservation therapies. Major trends expected during this period include the increasing adoption of advanced retinal imaging techniques, the rising use of minimally invasive vitreoretinal surgery, the growing integration of AI-based diagnostic tools, the expansion of targeted retinal therapies, and an enhanced focus on early disease detection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23574&type=smp

What Market Drivers Are Helping Shape The Vitreoretinal Disorder Market Expansion?

The expanding occurrence of diabetic retinopathy is projected to fuel the expansion of the vitreoretinal disorder market moving ahead. This eye ailment, diabetic retinopathy, arises from harm to retinal blood vessels resulting from elevated blood sugar concentrations in individuals with diabetes. The prevalence of diabetic retinopathy is on the rise, primarily attributed to the increasing spread of diabetes, which is spurred by inactive lifestyles and inadequate blood sugar management, leading to damage of the retinal blood vessels. Effective management of vitreoretinal disorder is vital in addressing diabetic retinopathy, as it tackles complications like vitreous hemorrhage and tractional retinal detachment, thus safeguarding vision and averting additional retinal harm. As an illustration, in October 2024, data from the Australian Institute of Health and Welfare, an Australia-based government body, indicated that in 2022–23, 1.8% of screened First Nations individuals in Australia underwent treatment for diabetic retinopathy. This figure represented a lower age-standardized treatment rate of 1.3% compared to non-Indigenous Australians, who had a rate of 1.5%. Consequently, the escalating incidence of diabetic retinopathy is propelling the expansion of the vitreoretinal disorder market.

How Is The Vitreoretinal Disorder Market Examined Through Segment Analysis?

The vitreoretinal disorder market covered in this report is segmented –

1) By Type: Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Macular Degeneration, Macular Hole, Other Types

2) By Diagnosis: Digital Fluorescein Angiography, Optical Coherence Tomography, Heidelberg Retinal Tomography, Indocyanine Green Angiography, Other Diagnosis

3) By Treatment: Surgery, Medication, Other Treatments

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Retinal Tear: Atrophic Retinal Tear, Operculated Retinal Tear, Horseshoe Retinal Tear, Giant Retinal Tear

2) By Retinal Detachment: Rhegmatogenous Retinal Detachment, Tractional Retinal Detachment, Exudative Retinal Detachment

3) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema

4) By Macular Degeneration: Dry Macular Degeneration, Wet Macular Degeneration

5) By Macular Hole: Full-Thickness Macular Hole, Lamellar Macular Hole, Tractional Macular Hole

6) By Other Types: Epiretinal Membrane, Retinal Vein Occlusion, Retinal Artery Occlusion, Retinitis Pigmentosa, Uveitis, Vitreous Hemorrhage, Macular Edema, Central Serous Retinopathy, Proliferative Vitreoretinopathy

Which Trends Are Influencing The Direction Of The Vitreoretinal Disorder Market?

Companies within the vitiligo treatment market are prioritizing clinical trials to develop innovative products like localized bromodomain and extra-terminal (BET) inhibitors gel therapies, which aim to safely reduce inflammation and encourage skin repigmentation. Localized bromodomain and extra-terminal (BET) inhibitors gel therapies are topical treatments that target BET proteins, which are involved in inflammatory gene activation. By applying these gels directly to depigmented skin, they diminish local inflammation and support melanocyte recovery, thereby fostering repigmentation while minimizing systemic side effects. For instance, in June 2024, VYNE Therapeutics, a US-based clinical-stage biopharmaceutical company, dosed the first subject in its Phase 2b trial of VYN201 (repibresib) gel, a novel once-daily pan-BET inhibitor specifically developed for nonsegmental vitiligo. This gel is being evaluated across three concentrations (1%, 2%, 3%) to locally suppress inflammation and support melanocyte recovery, providing a targeted approach with reduced systemic risk.

Which Companies Form The Competitive Landscape Of The Vitreoretinal Disorder Market?

Major companies operating in the vitreoretinal disorder market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., Topcon Corporation, Carl Zeiss Meditec AG, Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Clearside Biomedical, Apellis Pharmaceuticals Inc., Genentech Inc., Oxurion NV, Adverum Biotechnologies Inc., Opthea Limited, Graybug Vision Inc., Kiora Pharmaceuticals Inc., Allegro Ophthalmics Inc., Lineage Cell Therapeutics Inc., Ocugen Inc.

Access The Complete Vitreoretinal Disorder Market Report:

https://www.thebusinessresearchcompany.com/report/vitreoretinal-disorder-global-market-report

Which Region Contributes The Most To The Vitreoretinal Disorder Market?

North America was the largest region in the vitreoretinal disorder market in 2025. The regions covered in the vitreoretinal disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Vitreoretinal Disorder Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=23574&type=smp

Browse Through More Reports Similar to the Global Vitreoretinal Disorder Market 2026, By The Business Research Company

Retinal Disorder Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report

Vitrectomy Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/vitrectomy-devices-global-market-report

Optic Nerve Disorders Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/optic-nerve-disorders-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795